FY2025 Earnings Estimate for MediciNova Issued By B. Riley

MediciNova, Inc. (NASDAQ:MNOV - Free Report) - Research analysts at B. Riley issued their FY2025 earnings per share estimates for MediciNova in a report released on Monday, June 16th. B. Riley analyst M. Mamtani anticipates that the biopharmaceutical company will earn ($0.30) per share for the year. B. Riley has a "Strong-Buy" rating and a $5.00 price objective on the stock. The consensus estimate for MediciNova's current full-year earnings is ($0.24) per share. B. Riley also issued estimates for MediciNova's FY2026 earnings at ($0.33) EPS.

MediciNova (NASDAQ:MNOV - Get Free Report) last announced its quarterly earnings results on Tuesday, May 13th. The biopharmaceutical company reported ($0.06) earnings per share for the quarter, topping analysts' consensus estimates of ($0.14) by $0.08.

Several other analysts have also recently commented on the company. Wall Street Zen started coverage on MediciNova in a research report on Sunday, May 18th. They issued a "hold" rating on the stock. D. Boral Capital restated a "buy" rating and issued a $9.00 target price on shares of MediciNova in a research report on Wednesday, April 9th.

MediciNova Price Performance

MNOV opened at $1.26 on Wednesday. MediciNova has a 12 month low of $1.12 and a 12 month high of $2.55. The stock has a market cap of $61.80 million, a P/E ratio of -5.48 and a beta of 0.42. The stock's 50 day moving average price is $1.43 and its 200 day moving average price is $1.69.

Institutional Trading of MediciNova

Several large investors have recently added to or reduced their stakes in MNOV. Jane Street Group LLC boosted its stake in MediciNova by 64.5% during the 4th quarter. Jane Street Group LLC now owns 23,259 shares of the biopharmaceutical company's stock valued at $49,000 after purchasing an additional 9,121 shares in the last quarter. Millennium Management LLC boosted its position in shares of MediciNova by 26.7% in the fourth quarter. Millennium Management LLC now owns 25,923 shares of the biopharmaceutical company's stock worth $54,000 after buying an additional 5,470 shares during the period. Y Intercept Hong Kong Ltd acquired a new stake in shares of MediciNova in the fourth quarter worth $78,000. SBI Securities Co. Ltd. acquired a new stake in shares of MediciNova in the fourth quarter worth $113,000. Finally, Barclays PLC raised its holdings in shares of MediciNova by 15.5% during the fourth quarter. Barclays PLC now owns 95,600 shares of the biopharmaceutical company's stock worth $201,000 after acquiring an additional 12,800 shares in the last quarter. 9.90% of the stock is currently owned by institutional investors and hedge funds.

About MediciNova

MediciNova, Inc, a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.